Honasa buys 58% of Fluence Pharma at ₹135 cr, pushes Mamaearth parent into nutraceuticals
The Mamaearth and The Derma Co owner is acquiring a controlling 58% stake in nutraceutical firm Fluence Pharma at a ₹135 crore enterprise valuation, marking Honasa's first material step beyond beauty and personal care into ingestible wellness — a category adjacency rivals like Nykaa and HUL are also chasing.
What happened
Honasa Consumer, parent of Mamaearth and The Derma Co, will acquire a 58% stake in nutraceutical firm Fluence Pharma at an enterprise valuation of ₹135 crore,
Key facts
- 58% stake
- ₹135 crore enterprise valuation
Why this matters
At a ₹135 cr enterprise valuation for control, Fluence sets a reference comp for sub-scale Indian nutraceutical assets — expect Nykaa, HUL, and others to accelerate diligence on similar bolt-ons in ingestible wellness.